<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927911</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-413</org_study_id>
    <nct_id>NCT03927911</nct_id>
  </id_info>
  <brief_title>Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries</brief_title>
  <acronym>FUSION</acronym>
  <official_title>A Multicenter, Prospective, Active Controlled, Real World, Phase 4 Study of EXPAREL in Multimodal Regimens Compared With Standard of Care for Postsurgical Pain Management in Subjects Undergoing Lumbar Posterior Spine Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: The primary objective of this study is to compare postsurgical opioid
      consumption through 72 hours postsurgery in patients receiving local infiltration analgesia
      (LIA) with EXPAREL and bupivacaine HCl (EXPAREL group) with that of patients receiving
      standard of care (SOC) (control group) in adult subjects undergoing posterior lumbar spine
      surgeries where both groups are receiving a multimodal pain regimen.

      Secondary Objectives: The secondary objectives of this study are to:

        1. Compare safety and effectiveness outcomes following LIA with EXPAREL and bupivacaine
           hydrochloride (HCl) versus SOC in adult subjects undergoing posterior lumbar spine
           surgeries through 72 hours, including time to first opioid and opioid-related adverse
           events (ORAEs).

        2. Compare health outcomes following LIA with EXPAREL and bupivacaine hydrochloride (HCl)
           versus SOC in adult subjects undergoing posterior lumbar spine surgeries, including
           discharge readiness, hospital (or other facility) length of stay (LOS), discharge
           disposition, hospital readmissions, and health service utilization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 4, multicenter, prospective, active-controlled, real world, study in
      approximately 225 adult subjects undergoing posterior lumbar spine surgery under general
      anesthesia.

      Subjects will be screened within 30 days prior to surgery; screening on the day of surgery
      will be allowed but is discouraged. If a subject can only be screened on the day of surgery,
      the informed consent process must still be started at least 24 hours prior to the conduct of
      any screening procedures that are not considered SOC at the institution and such procedures
      may not be performed until written informed consent is provided. All screening procedures
      that are not SOC must be performed and documented within the 30-day time window (inclusive of
      the day of surgery for those subjects who can only be screened on the day of surgery) as
      described here.

      During the screening visit, subjects will be assessed for any past or present medical
      conditions that in the opinion of the investigator would preclude them from study
      participation. After the ICF is signed, the following information will be recorded and
      procedures done: medical history, surgical history, medication history, the subject's opioid
      use history will be recorded to calculate mean daily mg oral morphine equivalent dosing (MED
      PO) in the last 30 days, demographic and background information, height, weight and body mass
      index (BMI), a urine pregnancy test for women of childbearing potential, and the subject's
      current adverse experiences (AEs), if any.

      Subjects will be asked questions and/or be asked to fill forms as part of the following
      assessments: Brief Pain Inventory - short form (BPI-sf), 5-item Opioid Compliance Checklist
      (OCC), Hospital Anxiety and Depression Scale (HADS), Survey of Pain Attitudes (SOPA), Numeric
      Rating Scale (NRS) ti assess pain and Opioid Related Symptom Distress Scale (ORSDS).

      Based on the planned surgical procedure, subjects will be placed in one of three cohorts:

        -  Cohort 1 - Open lumbar spinal fusion technique; (&quot;open&quot; cohort)

        -  Cohort 2 - Minimally invasive tubular and/or percutaneous pedicle screw insertion for
           lumbar decompression with or without fusion;(&quot;tubular/percutaneous without midline
           incision&quot; cohort)

        -  Cohort 3 - Lumbar decompression surgery (LDS) without fusion (discectomy or laminectomy
           outpatient cohort)

      Number of Subjects (Planned):

      The initial sample size in each study cohort (i.e., cohort 1, cohort 2 and cohort 3) is
      estimated at 75 subjects (50 subjects with EXPAREL and 25 subjects with Control group), for a
      total of 225 subjects in all three cohorts. Within each assigned cohort, subjects will be
      allocated in a 2:1 ratio to the EXPAREL (50 subjects) and Control group (25 subjects).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-surgical opioid consumption in mg MED PO (0-72 hours)</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>Post-surgical opioid consumption in mg MED PO from 0 hours (end of surgery) to 72 hours postsurgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-surgical opioid consumption in mg MED PO at 14 days after surgery</measure>
    <time_frame>An average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid rescue through 72 hours or discharge.</measure>
    <time_frame>An average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Related Symptom Distress Scale (OR-SDS)</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>Opioid related adverse events will be assessed by using the Opioid Related Symptoms Distress Scale (OR-SDS) at 24, 48, and 72 hours postsurgery, at discharge, and at 14 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Postoperative Pain Management</condition>
  <arm_group>
    <arm_group_label>Open or mini-open surgical technique cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tubular or Percutaneous cohort (Minimally Invasive Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumbar decompression without fusion (Outpatient Cohort)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL and Bupivacaine</intervention_name>
    <description>Drug: EXPAREL and Bupivacaine HCl 0.5%</description>
    <arm_group_label>Lumbar decompression without fusion (Outpatient Cohort)</arm_group_label>
    <arm_group_label>Open or mini-open surgical technique cohort</arm_group_label>
    <arm_group_label>Tubular or Percutaneous cohort (Minimally Invasive Cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Lumbar decompression without fusion (Outpatient Cohort)</arm_group_label>
    <arm_group_label>Open or mini-open surgical technique cohort</arm_group_label>
    <arm_group_label>Tubular or Percutaneous cohort (Minimally Invasive Cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-75 years old at the time of screening.

          2. Primary surgical indication is related to spinal degenerative disease, including any
             of the following:

               1. Spinal stenosis

               2. Spondylolisthesis

               3. Radiculopathy/instability disc disorders

               4. Degenerative disc disease

          3. Medically cleared for elective spine surgery.

          4. Scheduled to undergo:

               1. Elective (i.e., not emergency)

               2. Lumbosacral (i.e., L1-S1)

               3. Posterior approach with posterior instrumentation

          5. Cohort 1 - Open cohort only: (Open or mini-open surgical technique with):

               1. 1-level (i.e., spanning 2 vertebrae) or 2-level (i.e., spanning 3 contiguous
                  vertebrae)

               2. Primary fusion or revision fusion

               3. Open or mini-open surgical technique

          6. Cohort 2 - Tubular or percutaneous cohort only:

               1. 1-level (i.e., spanning 2 vertebrae) or 2-level (i.e., spanning 3 contiguous
                  vertebrae)

               2. Primary fusion or revision fusion

               3. Tubular or percutaneous surgical technique

          7. Cohort 3 - Lumbar decompression without fusion outpatient cohort only:

               1. Radiculopathy

               2. Spinal stenosis

          8. Able to provide informed consent and adhere to all study assessments and visit
             schedule

        Exclusion Criteria:

          1. Serious spinal pathology determined by Investigator that might meaningfully affect
             postsurgical outcomes, including any of the following:

               1. Suspected cauda equina syndrome (e.g., bowel/bladder involvement)

               2. Infection

               3. Tumor

               4. Fracture

               5. Systemic inflammatory spondyloarthropathy

          2. Contraindication to local anesthesia according to the clinical judgment of the
             Investigator and based on the EXPAREL label.

          3. Patients who most likely will require PCA pumps in EXPAREL group.

          4. Anterior surgical approaches, including any of the following:

               1. Anterior lumbar interbody fusion (ALIF)

               2. Oblique lumbar interbody fusion (OLIF)

               3. Anterior-posterior or 360ยบ fusion

          5. Lateral surgical approaches, including any of the following:

               1. Extreme lateral interbody fusion (XLIF)

               2. Direct lateral interbody fusion (DLIF)

          6. High-dose presurgical opioid use:

             a) Mean daily intake greater than 100 mg mEq PO in the past 30 days

          7. Known allergy, hypersensitivity, or contraindication to any of the following study
             medications:

               1. Bupivacaine

               2. EXPAREL

               3. Tylenol (acetaminophen)

               4. Robaxin

               5. 2 or more NSAIDs

               6. 2 or more gabapentinoids

               7. 2 or more rescue opioids (e.g., oxycodone, morphine, hydromorphone)

               8. 2 or more medications for postoperative nausea, vomiting, or pruritus (e.g.,
                  dexamethasone, ondansetron)

          8. History of severely impaired renal or hepatic function.

          9. Severe chronic pain that requires analgesic treatment, and in the opinion of the
             principal Investigator, is likely to meaningfully impact postsurgical outcomes.

         10. Subjects that have implanted spinal cord stimulator or intrathecal drug pump.

         11. Any neurologic or psychiatric disorder that might impact postsurgical pain or
             interfere with study assessments per Investigator discretion.

         12. Malignancy in the last 2 years.

         13. History of misuse, abuse, or dependence on opioid analgesics, other prescription
             drugs, illicit drugs, or alcohol as defined in DSM-5. Dependence or chronic opioid use
             will be defined as use of more than 30 morphine equivalents per day during the prior
             90 days.

         14. Currently pregnant, nursing, or planning to become pregnant during the study or within
             1 month after study drug administration.

         15. Body Mass Index &lt; 17 kg/m2 or &gt;44 kg/m2 at screening

         16. Subjects receiving Worker's Compensation for disability or who are involved in other
             litigation related to the spine.

         17. Planned concurrent surgical procedure.

         18. Previous participation in an EXPAREL study.

         19. Administration of any investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug administration,
             or planned administration of another investigational product or procedure during the
             subject's participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayana Nagaraj, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marcus Neuroscience Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Orthopaedic Institute of Western Kentucky</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina NeuroSurgery &amp; Spine Associates, P.A.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3-Emerging Medical Research, LLC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Spine Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Surgical Hospital</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

